- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05218668
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) (REAL)
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study population will consist of subjects with a diagnosis of probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria; with ALS symptom onset within 48 months; and with percent predicted SVC ≥ 50% at Screening 1. Subjects must also have an average rate of decline in ALSFRS-R at Screening 1 of 0.5 to 3.0 points/month, with rate of decline calculated using historical data (either prior ALSFRS-R score or date of ALS symptom onset).
This study will be composed of a Primary Phase, with 24 weeks of open-label treatment, and an optional 12-month Extension Phase.
After consent, participants will undergo two screening evaluations, which will occur over the course of the 8 weeks prior to dosing with study drug. At Screening 1/Visit 1 (8 weeks before start of dosing), ALS assessments of ALSFRS-R/SVC/muscle dynamometry (HHD and hand grip) will be performed, as will safety assessments. Subjects who meet the pertinent inclusion/exclusion criteria will return for a second screening visit (Screening 2/Visit 2) approximately 4 weeks later, and ALS and safety assessment will again be conducted. Subjects who meet the pertinent Screening 2 study entry criteria will be enrolled into the study.
On Visit 3/Day 1, evaluations will be performed and dosing with study drug will begin. Dosing will be initiated at 180 mg/day; after at least 10 subjects have been enrolled and safely treated at 180 mg/day for 4 weeks, subsequent subjects may be enrolled at up to 240 mg/day. Participants will have an in-person or telephone visit at Week 1 (Visit 4) to assess for safety and drug compliance. Additional visits will occur at Weeks 4 (Visit 5), 8 (Visit 6), 12 (Visit 7), 18 (Visit 8) and 24 (Visit 9), during which ALS assessments of ALSFRS-R/SVC/HHD will be performed. For subjects who do not enter the Extension Phase, a final post-treatment follow-up visit (Visit 10) will be conducted at Week 25 (or 7±2 days after early termination).
For subjects who consent to continue in the Extension Phase, visits will occur every three months, during which ALS assessments will be done.
Blood biomarker collection will occur between enrollment and commencement of treatment, and at Week 12 (Visit 7) and Week 24 (Visit 9); during the extension phase it will occur on Visit 12 and Visit 14. CSF biomarker collection will occur between enrollment and commencement of treatment, and at Week 24 (Visit 9).
Laboratory safety assessments and adverse events will be collected at each study visit.
Subjects/caregivers will be asked to maintain a log of adverse events, study drug compliance, and medication changes, which will be reviewed at each visit.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ann C Tunstall, Ph. D.
- Phone Number: +1-703-981-8338
- Email: ann@woolseypharma.com
Study Contact Backup
- Name: Sabrina Williams
- Phone Number: +1-703-501-7820
- Email: sabrina@woolseypharma.com
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, NSW 2109
- Macquarie University Hospital
-
-
Queensland
-
Brisbane, Queensland, Australia, QLD 4029
- Royal Brisbane and Women's Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, VIC 3195
- Calvary Health Bethlehem Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85028
- Neuromuscular Research Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
Florida
-
Miami Lakes, Florida, United States, 33014
- Lakes Research
-
Tampa, Florida, United States, 33620
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Kentucky
-
Lexington, Kentucky, United States, 40506
- University of Kentucky
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Cox Medical Center
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between 18 and 75 years of age (inclusive) at Screening 1.
- Subject has had a diagnosis of probable laboratory-supported, probable, or definite ALS (as defined by El Escorial Revised ALS diagnostic criteria) by Screening 1, and no other cause of the neurological impairment has been identified by Screening 2.
- Average decrease in ALSFRS-R of 0.5 to 3 (inclusive) points per month, calculated using the most recent historical ALSFRS-R score from at least 3 months prior to Screening 1. If there is no qualifying previous score, an estimated rate will be calculated using the historical date of ALS symptom onset (weakness and/or dysarthria and/or dysphagia).
- Percent predicted SVC ≥ 50% at Screening 1.
- ALS symptom onset (weakness and/or dysarthria, and/or dysphagia) within 48 months of Screening 1.
Subjects taking riluzole, edaravone, or phenylbutyrate (PB) and/or tauroursodeoxycholic acid (TUDCA) may be included if the following criteria are met at Screening 1, and there is no change in treatment between Screening 1 and Enrollment:
- Stable dose of riluzole for at least 30 days;
- Stable dose of edaravone for at least 3 cycles; and/or
- Stable dose of PB and/or TUDCA for at least 90 days
Subjects taking any of these drugs prior to screening who intend to discontinue them before starting the study must have discontinued the drug(s) at least 28 days before Screening 1.
- Women of childbearing potential (WCBP) must agree to abstain from sex or use an adequate method of contraception for the duration of the screening period, the study drug treatment period, and for 28 days after the last dose of study drug.
- Males must agree to abstain from sex with WCBP or use an adequate method of contraception for the duration of the study drug treatment period and for 75 days after.
- Capable of providing informed consent and following trial procedures (where subject consents but is unable to sign the informed consent a legally authorized representative (LAR)/surrogate must sign on their behalf).
Exclusion Criteria:
- ALSFRS-R < 24 at Screening 1.
- Expected change in dosing of riluzole, edaravone, or PB and/or TUDCA between Screening 1 and the end of the study.
- Presence of other causes of neuromuscular weakness or other neurodegenerative diseases that could interfere with the objectives of the study or the safety of the subject, in the opinion of the Investigator.
- Mechanical ventilation via tracheostomy. (Use of non-invasive ventilation e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation is not an exclusion).
- Any medical condition (including cardiovascular, hematologic, renal, hepatic, or psychiatric diseases) that in the opinion of the Investigator would disallow safe participation in the trial or interpretation of the study results.
- Suicidal ideation per the Columbia-Suicide Severity Rating Scale (C-SSRS) that in the opinion of the Investigator would pose a safety risk.
- ALT ≥ 3 x upper limit of normal (ULN) or aspartate aminotransferase (AST) ≥ 3 x ULN at Screening 2.
- Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 at Screening 2.
- Participants who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule or study evaluations.
- Treatment in a clinical trial with another investigational drug within 28 days or 5 half-lives of drug before Screening 1, whichever is longer.
- Exposure at any time to any gene therapies under investigation for the treatment of ALS.
- Treatment with clenbuterol within 28 days of Screening 1, or any time between Screening 1 and enrollment.
- On more than one of the following drug classes: long-acting nitrates, beta-blockers, or calcium channel blockers. (Note: subjects may be on one of the drug classes.)
- Systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 60 mmHg at Screening 2. (Note: in the case of a systolic blood pressure < 90 and/or diastolic blood pressure < 60, BP measurements should be repeated after 10 minutes, and the higher reading used for Inclusion/Exclusion.)
- Known hypersensitivity to the active (fasudil) or inactive ingredients in the study drug.
- Known to be pregnant or lactating; or positive pregnancy test for WCBP.
- At Screening 2, neutrophil count < 1,500/mm3, platelets < 100,000/mm3, international normalized ratio (INR) > 1.5 or any contraindication to or unable to tolerate lumbar puncture, including use of anticoagulant medications that cannot be withheld. For example, if a subject is taking warfarin and it cannot be withheld for lumbar puncture, this would exclude the subject from study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fasudil
Oral fasudil up to 240 mg/day
|
Oral fasudil up to 240 mg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Through study completion, up to 25 weeks
|
Incidence of Adverse Events (AEs] and Serious Adverse Events (SAEs) as assessed by clinically significant abnormal physical examination findings; changes in vital signs; 12-lead electrocardiogram (ECG); magnetic resonance imaging (MRI); and hematology, blood chemistry, liver function, and urine tests.
|
Through study completion, up to 25 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the slope of the decline in percent predicted Slow Vital Capacity (SVC) during treatment vs pre-treatment
Time Frame: Monthly from Screening to Week 12; Every six weeks to Week 24
|
The SVC will be measured using the study-approved portable spirometer, and assessments will be performed using a face mask. Three SVC trials are required for each testing session, however up to 5 trials may be performed if the variability between the highest and second highest SVC is 10% or greater for the first 3 trials. The highest SVC recorded is utilized for eligibility. At least 3 measurable SVC trials must be completed to score SVC for all visits after screening. Predicted SVC values and percent predicted SVC values will be calculated using the Quanjer Global Lung Initiative equations. |
Monthly from Screening to Week 12; Every six weeks to Week 24
|
Change in the slope of the decline in muscle strength during treatment vs pre-treatment
Time Frame: Monthly from Screening to Week 12; Every six weeks to Week 24
|
A spring-loaded device that "breaks" at pre-set forces will be used to assess readings obtained by HHD throughout the study.
Grip strength dynamometry for both hands will be acquired, and the mean force in kilograms will be calculated.
Measures will be obtained from each hand in triplicate.
|
Monthly from Screening to Week 12; Every six weeks to Week 24
|
Change in the slope of the decline Revised ALS Functional Rating Scale (ALSFRS-R) during treatment vs pre-treatment
Time Frame: Monthly from Screening to Week 12; Every six weeks toWeek 24]
|
The ALSFRS-R is a validated rating instrument for monitoring the progression of disability inpatients with ALS and is utilized for monitoring functional change in ALS patients.
The score assesses various 4 domains including: (i) bulbar function (speech, salivation, swallowing); (ii)fine motor task (handwriting, cutting food and handling utensils, with or without gastrostomy, dressing and hygiene); (iii) gross motor task (turning in bed, walking, climbing stairs); and (iv)respiratory function (dyspnea, orthopnea and respiratory insufficiency).
|
Monthly from Screening to Week 12; Every six weeks toWeek 24]
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Membrane Transport Modulators
- Protein Kinase Inhibitors
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Fasudil
Other Study ID Numbers
- WP-0512-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Fasudil (WP-0512)
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)Active, not recruitingHIV | Sexually Transmitted InfectionsUnited States
-
University of Central FloridaNational Institute on Minority Health and Health Disparities (NIMHD); University...Recruiting
-
Federal University of Mato GrossoUnivag Centro UniversitárioRecruitingInsulin Resistance | Ketosis | Acute-Phase ResponseBrazil
-
Abramson Cancer Center at Penn MedicineRecruitingCervical Cancer | Uterine CancerUnited States
-
Columbia UniversityCompleted
-
Woolsey PharmaceuticalsCompleted
-
Technical University of MunichRecruitingIdiopathic Parkinson´s DiseaseGermany
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Brigham and Women's HospitalCompletedAtherosclerosis | HypercholesterolemiaUnited States